Liposomal tobramycin and ceftazidime improved antibacterial activity against Pseudomonas aeruginosa, suggesting their clinical potential as advanced nanocarriers.
Key Points
This research aims to develop and assess liposomal formulations of tobramycin and ceftazidime for better antibiotic delivery against Pseudomonas aeruginosa.
Developed liposomal formulations using active loading approach.
Characterized size, polydispersity, and morphology via TEM.
Conducted in-vitro release experiments at varied temperatures.
Performed antimicrobial tests to compare with free antibiotics.
Assessed colloidal stability over three weeks.
Liposomal tobramycin and ceftazidime showed nanoscale size and low polydispersity index.
Tobramycin release was 71% at 37 °C in 6 hours; ceftazidime sustained 80% over 48 hours.
Liposomal formulations reduced MIC of tobramycin by 2.78-fold and ceftazidime by 1.72-fold.
Demonstrated good colloidal stability with minimal size increase and stable zeta potential.